Loading
A phase 2 trial of Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and Polatuzumab vedotin in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) is a phase 2 interventional study registered as NCT06890884 by Merck Sharp & Dohme LLC, with 594 participants planned, started 2025-04-11 and due to reach its primary completion in 2027-12-13. Interventions recorded: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar and Prednisone.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin.
Shares Prednisone, Rituximab, Doxorubicin, Monoclonal antibodies and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Doxorubicin, Cyclophosphamide, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.